|
| Home : BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease |
|
Aug 23
2022 |
BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease |
|
National Agency for Safety of Medicines and Health Products (ANSM) and French Ethics Committee approve protocol for trial expected to begin in Q4 2022 RESEARCH TRIANGLE PARK, N.C. and PARIS, Aug. 23, 2022 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/brainvectis-a-subsidiary-of-askbio-receives-clearance-to-conduct-phase-iii-clinical-trial-in-france-for-its-novel-gene-therapy-for-early-stage-huntingtons-disease-301610417.html |
| |
|
Related News
|
» Royale Group Expanding to Second Delaware Location
» Wemade Holds the 1st Anniversary Event of MIR4 Global Service!
|
|
|
